Zobrazeno 1 - 6
of 6
pro vyhledávání: '"T. N. Pushkar"'
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 15, Iss 3, Pp 76-81 (2023)
Cefepime is a fourth-generation cephalosporin antibiotic widely used in clinical practice for various organ systems pathology treatment. The article describes the clinical observation of a patient who, 3 days after cefepime administration, had a decr
Externí odkaz:
https://doaj.org/article/a040a8cbf46b4d2fb96c7f87198b90c1
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 13, Iss 3, Pp 67-74 (2021)
Oxcarbazepine (OXC) is an antiepileptic drug (AED) used in children and adults as initial and adjunctive therapy for focal epilepsy (FE). It has been used in Russia since 2007; however, only a few studies have been published on its use in Russian pat
Externí odkaz:
https://doaj.org/article/a6d3e8ddafa0435eb73fccdebd780a57
Publikováno v:
Эпилепсия и пароксизмальные состояния, Vol 12, Iss 3, Pp 137-146 (2020)
Introduction. Oxcarbazepine (OXC) is approved for initial and adjunctive therapy of focal epilepsy (FE), being also a drug of choice in case of pediatric FE. Despite that OXC has been used in the Russian Federation (RF) since 2007, studies assessing
Externí odkaz:
https://doaj.org/article/2e732cbccf5049f5bf0b77bbe7047c2b
Publikováno v:
Nevrologiâ, Nejropsihiatriâ, Psihosomatika, Vol 13, Iss 3, Pp 67-74 (2021)
Oxcarbazepine (OXC) is an antiepileptic drug (AED) used in children and adults as initial and adjunctive therapy for focal epilepsy (FE). It has been used in Russia since 2007; however, only a few studies have been published on its use in Russian pat
Publikováno v:
Neuroscience and Behavioral Physiology. 51:289-297
Objectives. To assess the dynamics of the index of epileptiform activity (IEA) as indicator of the efficacy and tolerance of treatment with valproic acid formulations in patients with new diagnoses of generalized and focal epilepsy. Materials and Met
Publikováno v:
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 120:35
To evaluate the changes of epileptiform activity index (EAI) as a measure of the efficacy and tolerability of treatment with valproic acid (VA) in patients with newly-diagnosed generalized and focal epilepsy.The study included 93 patients (55 men and